Quantification of blood-brain barrier (BBB) leakage is of main interest in the stroke field to identify patients susceptible to develop hemorrhage and to identify the therapeutic window for neuroprotective drugs administration. We used small (Gd-DOTA) and medium size (nanoparticles AGuIX) contrast agents (CA) to quantify BBB permeability 60-to-90 minutes post-recanalization in a model of stroke using dynamic contrast-enhanced (DCE) MRI. We confirmed 1) Early BBB leakage with both CA and 2) BBB opening to nanoparticles at post-recanalization provides opportunity for selective neuroprotection drug delivery.
This abstract and the presentation materials are available to members only; a login is required.